SEC 13F Intelligence

Managers / Q2 2024 · view latest →

SECTORAL ASSET MANAGEMENT INC

CIK 0001274413 · 1010 SHERBROOKE ST., WEST, SUITE 1610, MONTREAL, A8, H3A 2R7 · 514 849 8777

Reported Value
$246M
Q2 2024
Positions
97
Filings on Record
30
2019–present window
Filed
Aug 13, 2024
original filing

Summary

Sectoral Asset Management Inc reported $246M in U.S.-listed holdings across 97 positions for Q2 2024.

Its largest position, LLY, represents 8.6% of the portfolio.

Compared with Q1 2024, the fund opened 14 new positions and exited 9.

Portfolio Metrics

Turnover
+17.1%
vs prior filed quarter
Top-10 Concentration
+46.1%
share of reported value
Largest Position
+8.6%
Lilly Eli
New / Exited
14 / 9
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $736MQ4 ’18Q1 ’19: $831MQ2 ’19: $836MQ3 ’19: $580MQ4 ’19: $670MQ4 ’19Q1 ’20: $521MQ2 ’20: $1.1BQ3 ’20: $1.2BQ4 ’20: $1.4BQ4 ’20Q1 ’21: $1.3BQ2 ’21: $1.2BQ3 ’21: $1.2BQ4 ’21: $664MQ4 ’21Q1 ’22: $563MQ2 ’22: $496MQ3 ’22: $508MQ4 ’22: $517MQ4 ’22Q1 ’23: $520MQ2 ’23: $600MQ3 ’23: $514MQ4 ’23: $232MQ4 ’23Q1 ’24: $254MQ2 ’24: $246MQ3 ’24: $169MQ4 ’24: $150MQ4 ’24Q1 ’25: $128MQ2 ’25: $151MQ3 ’25: $162MQ4 ’25: $125MQ4 ’25Q1 ’26: $121Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 91.3%Other: 5.3%ADR: 3.4%
  • Common Stock · 91.3% · $225M
  • Other · 5.3% · $13M
  • ADR · 3.4% · $8M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CTNMCONTINEUM THERANEW+800.9K800.9K+$14M$14M
CVSCVS HEALTH CORPNEW+39.0K39.0K+$2M$2M
STEVANATO GROUP SPANEW+89.0K89.0K+$2M$2M
EVHEVOLENT HEALTH INCNEW+84.0K84.0K+$2M$2M
BMYBRISTOL MYERS SQUIBBNEW+30.0K30.0K+$1M$1M
CITHE CIGNA GROUPNEW+3.5K3.5K+$1M$1M
BDXBECTON DICKINSONNEW+4.0K4.0K+$934,840$934,840
ADC THERAPEUTICS SANEW+228.1K228.1K+$720,802$720,802

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2024

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1LLYLILLY ELI & COhistory →COM8.62%$21M23.4K
2LENZLENZ THERAPEUTICShistory →COM7.62%$19M1.08M
3CTNMCONTINEUM THERAhistory →CL A5.73%$14M800.9K
4UNHUNITEDHEALTH GRP INChistory →COM5.52%$14M26.7K
5MRKMERCK & CO INChistory →COM4.35%$11M86.5K
6JNJJOHNSON & JOHNSONhistory →COM3.38%$8M56.9K
7ABBVABBVIE INChistory →COM3.13%$8M45.0K
8ABTABBOTT LABShistory →COM2.80%$7M66.2K
9REGNREGENERON PHARMCTCLShistory →COM2.58%$6M6.0K
10TMOTHERMO FISHER SCIhistory →COM2.36%$6M10.5K
11BSXBOSTON SCIENTIFIChistory →COM2.24%$6M71.5K
12MLYSMINERALYS THERAPEUTIhistory →COM2.09%$5M438.7K
13PFEPFIZER INChistory →COM2.06%$5M181.4K
14GILDGILEAD SCIENCES INChistory →COM1.92%$5M68.8K
15MEDTRONIC PLCSHS1.90%$5M59.6K
16AMGNAMGEN INChistory →COM1.87%$5M14.7K
17DHRDANAHER CORPhistory →COM1.80%$4M17.7K
18SYKSTRYKER CORPhistory →COM1.78%$4M12.8K
19VRTXVERTEX PHARMAhistory →COM1.65%$4M8.7K
20DC4DEXCOM INChistory →COM1.48%$4M32.1K
21BMRNBIOMARIN PHARMAC INChistory →COM1.38%$3M41.3K
22IQVIQVIA HOLDINGS INChistory →COM1.34%$3M15.6K
23ALNYALNYLAM PHARMACUETCLhistory →COM1.23%$3M12.5K
24ZBHZIMMER BIOMET HLDShistory →COM1.18%$3M26.6K
25ARGXARGENX SEhistory →SPN ADR1.14%$3M6.5K
26BOLDBOUNDLESS BIO INChistory →COM1.07%$3M682.3K
27MRNAMODERNA INChistory →COM1.07%$3M22.1K
28PCVXVAXCYTE INChistory →COM1.04%$3M33.7K
29ICON PLCSHS1.02%$3M8.0K
30ELVELEVANCE HEALTH INCCOM0.99%$2M4.5K
31ISRGINTUITIVE SURGIC INCCOM0.98%$2M5.4K
32CVSCVS HEALTH CORPCOM0.94%$2M39.0K
33BNTXBIONTECH SESPN ADR0.89%$2M27.3K
34AM6AMICUS THERAPEUTICSCOM0.87%$2M216.8K
35SRPTSAREPTA THERAPEUTICSCOM0.87%$2M13.5K
36GDRXGOODRX HLDGS INCCOM0.84%$2M265.0K
37SPRYARS PHARMACEUTICALSCOM0.82%$2M236.9K
38PGNYPROGYNY INCCOM0.81%$2M70.0K
39CYTKCYTOKINETICS INCCOM0.81%$2M36.9K
40INARI MED INCCOM0.79%$2M40.5K
41OPCHOPTION CARE HEALTHCOM0.73%$2M65.0K
42HUMHUMANA INCCOM0.72%$2M4.8K
43AZNNASTRAZENECASPN ADR0.69%$2M21.6K
44STEVANATO GROUP SPAORD SHS0.66%$2M89.0K
45EVHEVOLENT HEALTH INCCL A0.65%$2M84.0K
46PODDINSULET CORPCOM0.60%$1M7.3K
47EWEDWARDS LIFESCIENCECOM0.59%$1M15.7K
482662247DITEOS THERAPEUTICSCOM0.58%$1M97.0K
49BIIBBIOGEN INCCOM0.58%$1M6.1K
50TURNSTONE BIOLOGICSCOM0.55%$1M517.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$121M77May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$125M74Feb 9, 202613F-HRchanges · EDGAR ↗
Q3 2025$162M82Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$151M94Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$128M84May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$150M86Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$169M90Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$246M97Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$254M92May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$232M104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$514M123Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$600M121Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$520M118May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$517M120Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$508M109Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$496M112Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$563M106May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$664M108Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.2B127Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.3B113May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.4B97Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.2B88Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B191Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$521M65May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$670M65Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$580M63Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$836M92Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$831M106May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$736M104Feb 12, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.